Heterozygous familial hypercholesterolemia (heFH) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Heterozygous familial hypercholesterolemia (heFH) – Pipeline Review, H2 2017’, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH)

The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Heterozygous familial hypercholesterolemia (heFH) therapeutics and enlists all their major and minor projects

The report assesses Heterozygous familial hypercholesterolemia (heFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Madrigal Pharmaceuticals Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Heterozygous familial hypercholesterolemia (heFH) - Overview 5

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Products under Development by Companies 8

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 9

Assessment by Target 9

Assessment by Mechanism of Action 11

Assessment by Route of Administration 13

Assessment by Molecule Type 14

Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 15

Daewoong Co Ltd 15

Esperion Therapeutics Inc 15

Gemphire Therapeutics Inc 16

Madrigal Pharmaceuticals Inc. 16

Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles 17

(bempedoic acid + ezetimibe) - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

gemcabene calcium - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

MGL-3196 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

MGL-3745 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ST-103 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 30

Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products 31

Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 32

Featured News & Press Releases 32

Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 32

Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit 33

Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 35

May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196 35

Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia 36

Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia 37

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Tables

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Products under Development by Companies, H2 2017 8

Number of Products by Stage and Target, H2 2017 10

Number of Products by Stage and Mechanism of Action, H2 2017 12

Number of Products by Stage and Route of Administration, H2 2017 13

Number of Products by Stage and Molecule Type, H2 2017 14

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Daewoong Co Ltd, H2 2017 15

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Esperion Therapeutics Inc, H2 2017 15

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Gemphire Therapeutics Inc, H2 2017 16

Heterozygous familial hypercholesterolemia (heFH) – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 16

Heterozygous familial hypercholesterolemia (heFH) – Dormant Projects, H2 2017 30

Heterozygous familial hypercholesterolemia (heFH) – Discontinued Products, H2 2017 31

List of Figures

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products by Targets, H2 2017 9

Number of Products by Stage and Targets, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 11

Number of Products by Stage and Routes of Administration, H2 2017 13

Number of Products by Stage and Molecule Types, H2 2017 14

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports